NCT/Study#

NCT04277637 /

BGB-11417-101

A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies

A Phase 1/1b Open-Label Dose Escalation and Expansion
Study of Bcl-2 Inhibitor BGB-11417 in Patients with
Mature B-Cell Malignancies

DISEASE GROUP:
Lymphoma
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: